MedTrace Logo

Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical Trial

NCT01851850 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2020-03-16

No results posted yet for this study

Summary

The purpose of the study is to extend the use of opicapone 25 or 50mg once per day by subjects who participated in the BIA 9-1067-302 clinical trial according form 4a for additional three years.

Conditions

  • Parkinson Disease

Interventions

DRUG

Opicapone

25mg or 50mg once per day

Sponsors & Collaborators

  • Rabin Medical Center

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2016-05-24
Completion
2016-05-24

Countries

  • Israel

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01851850 on ClinicalTrials.gov